Emricasan | pan-Caspase inhibitor
NMR (Conforms)
Available Options
| Size: | Price | Quantity | |
|---|---|---|---|
| 5 mg | $70.00 | ||
| 25 mg | $245.00 |
Emricasan (254750-02-2) is a liver-targeted antiapoptotic pan-caspase inhibitor.1,2 It has been investigated as a hepatoprotective agent in the treatment of liver ischemia3 and NASH/NAFLD liver injury4,5. Emricasan protected SNB-19 cells against cell death induced by Zika virus strains MR766, FSS13025, and PRVABC59.6 Emricasan improves the viability of hPSCs and their differentiated progeny when used in a small molecule cocktail (CEPT) containing chroman 1 (Cat# 10-4912), polyamines, and trans-ISRIB (Cat# 10-1539).7
References/Citations:
- Linton et al. (2005), First-in-class Pan Caspase Inhibitor for the Treatment of Liver Disease; J. Med. Chem., 48 6779
- Hoglen et al. (2004), Characterization of IDN-6556 (3-{2-(2-tert-Butylphenylaminooxalyl)-amino]-propionylamino}-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)-pentanoic Acid): a Liver-Targeted Caspase Inhibitor; J. Pharmacol. Exp. Ther., 309 634
- Hoglen et al. (2007), A caspase inhibitor, IDN-6556, ameliorates early hepatic injury in an ex vivo rat model of warm and cold ischemia; Liver Transpl., 13 361
- Barreyro et al. (2015), The pan-caspase inhibitor Emricasan (IDN-5665) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis; Liver Int., 35 953
- Frenette et al. (2019), Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-Stage Liver Disease Scores Compared With Placebo; Clin. Gastroenterol. Hepatol., 17 774
- Xu et al. (2016), Identification of small molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen; Nat. Med., 22 1101
- Chen et al. (2021), A versatile polypharmacology platform promotes cytoprotection and viability of human pluripotent and differentiated cells; Nat. Methods, 18 528
NMR (Conforms)
Safety Data Sheet:
Product Data Sheet:
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Emricasan (254750-02-2) is a liver-targeted antiapoptotic pan-caspase inhibitor.1,2 It has been investigated as a hepatoprotective agent in the treatment of liver ischemia3 and NASH/NAFLD liver injury4,5. Emricasan protected SNB-19 cells against cell death induced by Zika virus strains MR766, FSS13025, and PRVABC59.6 Emricasan improves the viability of hPSCs and their differentiated progeny when used in a small molecule cocktail (CEPT) containing chroman 1 (Cat# 10-4912), polyamines, and trans-ISRIB (Cat# 10-1539).7
References/Citations:
- Linton et al. (2005), First-in-class Pan Caspase Inhibitor for the Treatment of Liver Disease; J. Med. Chem., 48 6779
- Hoglen et al. (2004), Characterization of IDN-6556 (3-{2-(2-tert-Butylphenylaminooxalyl)-amino]-propionylamino}-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)-pentanoic Acid): a Liver-Targeted Caspase Inhibitor; J. Pharmacol. Exp. Ther., 309 634
- Hoglen et al. (2007), A caspase inhibitor, IDN-6556, ameliorates early hepatic injury in an ex vivo rat model of warm and cold ischemia; Liver Transpl., 13 361
- Barreyro et al. (2015), The pan-caspase inhibitor Emricasan (IDN-5665) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis; Liver Int., 35 953
- Frenette et al. (2019), Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-Stage Liver Disease Scores Compared With Placebo; Clin. Gastroenterol. Hepatol., 17 774
- Xu et al. (2016), Identification of small molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen; Nat. Med., 22 1101
- Chen et al. (2021), A versatile polypharmacology platform promotes cytoprotection and viability of human pluripotent and differentiated cells; Nat. Methods, 18 528
Related products
-
Acalabrutinib | Highly selective BTK inhibitor
From $45.00CAS:1420477-60-6Catalog Number:10-4806Alternate Name:ACP-196Activity:Highly selective BTK inhibitorChemical Name:4-[8-Amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamideMolecular Weight:465.52Molecular Formula:C26H23N7O2Solubility:Soluble in DMSO (up to at least 25 mg/ml)Physical Properties:Yellow solidPurity:98% by HPLC
NMR (Conforms)Storage Temperature:-20°CStability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.Shipping Code:RT -
BI 2536 | Dual Plk/BRD4 inhibitor – Destabilizes Myc
From $75.00CAS:755038-02-9Catalog Number:10-4121Activity:Dual Plk/BRD4 inhibitor – Destabilizes MycChemical Name:4-[[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-3-methoxy-N-(1-methylpiperidin-4-yl)benzamideMolecular Weight:521.67Molecular Formula:C28H39N7O3Solubility:Soluble in DMSO (up to 20 mg/ml) or in Ethanol (up to 25 mg/ml)Physical Properties:Off-white solidPurity:97% by HPLC
NMR (Conforms)Storage Temperature:-20°CStability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.Shipping Code:RT -
Elafibranor | PPARalpha/delta agonist
From $65.00CAS:923978-27-2Catalog Number:10-3901Activity:PPARalpha/delta agonistChemical Name:2-[2,6-Dimethyl-4-[(E)-3-(4-methylsulfanylphenyl)-3-oxoprop-1-enyl]phenoxy]-2-methylpropanoic acidAlternate Name:GFT505Molecular Weight:384.49Molecular Formula:C22H24O4SSolubility:Soluble in DMSO (up to at least 25 mg/ml).Physical Properties:Pale yellow solidPurity:98% by HPLC
NMR (Conforms)Storage Temperature:-20°Stability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 1 month.Shipping Code:RT
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
